What is it about?

This paper reports findings from a double-masked randomised controlled trial that investigated the effects of oral long-chain omega-3 fatty acid supplementation on peripheral nerve health in individuals with type 1 diabetes, over six months. Based on findings from our recent systematic review (Zhang et al., Nutr Rev, 2020), this is, to our knowledge, the first double-masked RCT to investigate this clinical question.

Featured Image

Why is it important?

Our major finding is that, relative to placebo, six months of oral long-chain omega-3 fatty acid supplementation promotes neuroregeneration in corneal sensory nerve fibres. These data provide the first robust evidence for oral omega-3 fatty acid supplementation as a disease-modifying intervention that improves small nerve fibre health in individuals with diabetes.

Read the Original

This page is a summary of: Investigating the Neuroprotective Effect of Oral Omega-3 Fatty Acid Supplementation in Type 1 Diabetes (nPROOFS1): A Randomized Placebo-Controlled Trial, Diabetes, May 2021, American Diabetes Association,
DOI: 10.2337/db21-0136.
You can read the full text:



The following have contributed to this page